A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: The Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI)

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 8, 2008, Pages 611-616

  Nijpels, G ^a   Boorsma, W ^a   Dekker, J M ^a   Kostense, P J ^a   Bouter, L M ^a   Heine, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acarbose; Beta cell function; Impaired glucose tolerance; Insulin secretion; Prevention type 2 diabetes; Randomized control trial

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; ANTIDIABETIC AGENT; INSULIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; BODY MASS; CAUCASIAN; DRUG EFFECT; GENETIC PREDISPOSITION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INCIDENCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; SECRETION; STATISTICS; WAIST HIP RATIO; WORLD HEALTH ORGANIZATION;

ACARBOSE; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; NETHERLANDS; PLACEBOS; RISK FACTORS; WAIST-HIP RATIO; WORLD HEALTH ORGANIZATION;

EID: 60849095141     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.839     Document Type: Article

References (25)

1. Harris M. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12: 464-474.
2. Harris M, Hadden W, Knowler W, Bennett P. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-534.
3. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident Type 2 diabetes in a Dutch population: the Hoorn study. JAMA 2001; 285: 2109-2113.
4. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141.
5. Pyorala K, Laakso M. Uusitupa M Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
6. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41-49.
7. Fuller J, Shipley M, Rose G, Jarrett R, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 1: 1373-1376.
8. Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
9. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J 2003; 24: 1406-1413.
10. Jarrett R, Keen H, McCartney P. The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabet Med 1984; 1: 279-283.
11. Keen H, Jarrett R, McCartney P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 1982; 22: 73-78.
12. Knowler W, Pettitt D, Everhart J, Slaine K, Bennett P, Mott D. Rate of deterioration of impaired glucose tolerance to diabetes and the effect of age, obesity and serum insulin. Diabetologia 1986; 29: A558.
13. French L, Boen J, Martinez A, Bushhouse S, Sprafka J, Goetz F. Population-based study of impaired glucose tolerance and type II diabetes in Wadena, Minnesota. Diabetes 1990; 39: 1131-1137.
14. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to DM2 in subjects with impaired glucose tolerance; The Hoorn Study. Diabetologia 1996; 39: 113-118.
15. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
16. Pan XR, Li GW, Hu YH, et al, The Da Qing IGT and Diabetes Study. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20: 537-544.
17. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
18. Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
19. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
20. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004; 47: 969-975.
21. Taylor R, Jenkins D, Barker H, et al. Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption. Diabetes Care 1982; 5: 92-96.
22. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190-1193.
23. Laar van de FA, Lucassen PL, Akkermans RP, Lisdonk van de EH, Rutten GE, Weel van C. α-Glucosidase inhibitors for patients with type 2 diabetes; Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 166-175.
24. Chang-Yu Pan, Yan Gao, Jia-Wei Chen, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003; 61: 183-190.
25. Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglemia does not appear to delay progression of early type 2 diabetes. Diabetes Care 2006; 29: 2095-2101.